SynthesisFrontiers in neurology2025
Tenecteplase in large-vessel occlusion with or without thrombectomy: a meta-analysis.
Synthesis in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite the growing adoption of Tenecteplase for stroke thrombolysis, key questions such as the role of bridging therapy and extended-window use in large-vessel occlusion (LVO) patients with or without access to endovascular thrombectomy (EVT) remain unresolved. Methods: We conducted a systematic review of randomized clinical trial (RCT) data involving LVO patients who were treated with or without Tenecteplase. Outcomes were stratified by EVT status, and further subgroup analysis based on treatment window (≤4.5 vs. > 4.5 h) was conducted. Generalized odds ratios (gORs) were used to assess disability reduction by modified Rankin Scale (mRS) shift analysis. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for functional independence (mRS 0-2), excellent outcome (mRS 0-1), mortality, and symptomatic intracranial hemorrhage (sICH). Results: Five studies (2,054 patients) were included. Treatment with Tenecteplase was associated with greater disability reduction (gOR, 1.19; 95% CI, 1.06-1.34), more excellent outcome (RR, 1.21; 95% CI, 1.06-1.38) and functional independence (RR, 1.14; 95% CI, 1.03-1.26) compared to no thrombolysis. Rates of sICH (RR, 1.46; 95% CI, 0.87-2.54) and mortality (RR, 1.07; 95% CI, 0.84-1.36) were similar between groups. Before EVT, Tenecteplase within 4.5 h was associated with greater disability reduction and higher functional independence compared with EVT alone; however, no benefit was observed beyond 4.5 h in those undergoing EVT. Among LVO patients not treated with EVT but with salvageable tissue on CT perfusion, Tenecteplase administered after 4.5 h was associated with improved functional outcomes. Conclusion: In this meta-analysis, Intravenous Tenecteplase was associated with improved outcomes when administered before EVT within 4.5 h and in the extended window, guided by advanced neuroimaging, among selected patients who lacked access to EVT. Systematic review registration: CRD420251115406.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.